John Campbell, Ph.D., said Moderna’s clinical trial reported substantially higher rates of adverse reactions among people who received its new mRNA flu vaccine than among those who received a standard flu vaccine. He also questioned why the FDA approved the vaccine one year after HHS announced a federal wind-down of mRNA vaccine development.

https://tdefender.substack.com/p/new-mrna-flu-vaccine-much-higher-adverse-reactions-standard-flu-shot-campbell?